Economic Burden and Medical Insurance Impact of the Different Dialysis for End-stage Renal Diseases

  • Dan GAO Dept. of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
  • Sanhui JING Dept. of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
  • Jian WU College of Public Health, Zhengzhou University, Zhengzhou, Henan, China
  • Ge WU Dept. of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Keywords: End stage renal disease, Hemodialysis, Peritoneal dialysis, Medical insurance

Abstract

Abstract Methods: Overall, 156 ESRD patients were enrolled at the Department of Nephrology in the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China between Jan 2013 and Jan 2014. They were divided into hemodialysis group (HD group, n=84) and peritoneal dialysis group (PD group, n=72). The data, such as the patient's basic information, total expenses and self-paid expenses in the early stage of dialysis and 1-year treatment, and medical insurance type, were separately collected.    

References

1. Collins AJ, Foley RN, Chavers B et al (2012). United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end - stage renal disease in the United States. Am J Kidney Dis, 59(1): A7, e1-420.
2. Zhang L, Wang F, Wang L et al (2012). Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet, 379 (9818): 815-22.
3. Lin B, Shao L, Luo Q et al (2014). Preva-lence of chronic kidney disease and its association with metabolic diseases: a cross-sectional survey in Zhejiang prov-ince, Eastern China. BMC Nephrology, Feb 21;15:36.
4. Choy AS, Li PK (2015). Sustainability of the Peritoneal Dialysis-First Policy in Hong Kong. Blood Purif, 40:320-25.
5. Atapour A, Eshaghian A, Taheri D et al (2015). Hemodialysis Versus Peritoneal Dialysis, which is Cost-effective? Saudi J Kidney Dis Transpl, 26(5):962
Published
2018-11-01
How to Cite
1.
GAO D, JING S, WU J, WU G. Economic Burden and Medical Insurance Impact of the Different Dialysis for End-stage Renal Diseases. IJPH. 47(11):1675-80.
Section
Original Article(s)